Regeneron Pharmaceuticals (NASDAQ:REGN) Director Huda Zoghbi Sells 7,439 Shares of Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Huda Zoghbi sold 7,439 shares of the stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $970.46, for a total transaction of $7,219,251.94. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,652,693.38. The trade was a 81.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Regeneron Pharmaceuticals Stock Down 3.0%

REGN traded down $28.31 during trading on Thursday, hitting $902.36. The stock had a trading volume of 1,398,293 shares, compared to its average volume of 833,634. The stock has a 50 day simple moving average of $800.69 and a two-hundred day simple moving average of $741.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 3.35. Regeneron Pharmaceuticals, Inc. has a twelve month low of $591.52 and a twelve month high of $991.73. The company has a market capitalization of $92.91 billion, a PE ratio of 19.92, a PEG ratio of 1.45 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. During the same period in the prior year, the firm posted $11.83 earnings per share. The business’s quarterly revenue was up 36.3% on a year-over-year basis. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 51.64 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.30%.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in REGN. LCM Capital Management Inc grew its position in Regeneron Pharmaceuticals by 2.2% in the 3rd quarter. LCM Capital Management Inc now owns 616 shares of the biopharmaceutical company’s stock valued at $467,000 after buying an additional 13 shares during the last quarter. Arjuna Capital increased its stake in Regeneron Pharmaceuticals by 3.2% in the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after buying an additional 14 shares during the period. Oakworth Capital Inc. raised its position in Regeneron Pharmaceuticals by 25.0% during the 3rd quarter. Oakworth Capital Inc. now owns 70 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 14 shares during the last quarter. Geneos Wealth Management Inc. raised its position in Regeneron Pharmaceuticals by 1.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company’s stock worth $645,000 after buying an additional 15 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 69 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 16 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Wall Street Zen raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. JPMorgan Chase & Co. upped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the company an “overweight” rating in a report on Friday, October 30th. TD Cowen increased their price objective on shares of Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the company a “buy” rating in a research report on Wednesday, October 21st. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. Finally, Raymond James Financial lifted their target price on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $898.97.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron advanced ALN-CIDEB into a Phase 3 study for liver disease, marking progress for its clinical pipeline. The available report did not provide further trial details. Regeneron advances ALN-CIDEB
• Positive Sentiment: The company joined the Mary Tyler Moore Vision Initiative consortium as a founding member, adding to its involvement in vision research. Regeneron joins vision initiative consortium
• Positive Sentiment: Recent coverage cited favorable earnings-estimate revisions, analyst price-target increases, and Bank of America’s addition of REGN to its Value 10 list. These follow a recent quarterly earnings and revenue beat, though much of this news predates today’s session. Analyst outlook and estimate revisions BofA adds REGN to Value 10 list
• Negative Sentiment: EVP Joseph Larosa sold 4,466 shares worth about $4.3 million, and director Christine Poon sold 7,830 shares. These disclosures may weigh on sentiment, although insider sales do not necessarily signal concerns about the business. EVP stock sale

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.